Conclusions: Many laboratories were unaware ofcurrent recommendations for screening for hypercholesterolaemia in the community. The present survey indicated an urgent need for the introduction ofbetter reference methods, standardisation, and quality assurance procedures before apolipoproteins become a routine part of coronary heart disease risk assessment.
The detection and management of patients with disorders of lipoprotein metabolism are provoking considerable interest. This is because clinical trial results have shown that lowering serum cholesterol reduces coronary heart disease morbidity' 2 and angiographic evidence that effective treatment of hyperlipidaemia may limit the progression or induce regression of atherosclerosis."' As a result several sets of consensus guidelines for desirable limits for blood lipid concentrations and the treatment by which these may be achieved have been published. '9 These recommendations make two assumptions:
1 That (a) in eight, lipoprotein lipase activity (or post-heparin lipolytic activity) in seven. A list of laboratories that are prepared to offer these and some additional services to other departments, together with conditions for accepting specimens, will be provided on request (MFL). Methods used for apolipoprotein determinations were radial immunodiffusion (8), electroimmunoassay (4), radioimmunoassay (3) and immunoturbidometric procedures (20) . Apolipoprotein assays were standardised using a variety of commercial material. There is no national EQAS for apolipoproteins.
Discussion
Findings from a questionnaire for which a response rate of81 % was obtained may be open to bias as it is likely that those most interested in the subject of the questionnaire will have responded. The response rate was high, however, and it seems likely that our data are representative of practice in the United Kingdom. All laboratories used enzymatic techniques for measuring serum cholesterol and triglyceride concentrations using a variety of analysers; no laboratory was using Liebermann-Burchard colorimetric methods. Improvements in interlaboratory comparability of cholesterol analyses have been noted in recent years, attributed, in part, to the use of more specific enzyme reagents and improved automated analysers. Imprecision, however, still varies between 2-2 and 13-7% with these techniques.'0 The present survey shows that there is considerable diversity in calibration procedures. Improvements in analytic performance have been reported when serum calibrators are used with values assigned using the US Centers for Disease Control (CDC) modification of the Abell-Kendall procedure for estimating cholesterol.'2 Minimisation of bias (inaccuracy) and interassay imprecision values of less than 3% should be the aim for tests which should be interpreted on the basis of risk of coronary heart disease rather than by comparison with reference values from local populations in which high serum cholesterol concentrations are prevalent."9 Many laboratories (35%) are still using outdated high reference ranges for serum cholesterol concentrations.
It is particularly noteworthy in the light of recent recommendations with regard to screening for hypercholesterolaemia that 49% of laboratories still insisted on fasting blood samples. This is a major obstacle to screening in the community, being an concentrations" 19 20 for assessing coronary heart disease risk. Inclusion of these investigations in lipoprotein assessment would increase costs and more information from prospective as opposed to case-control studies is required before a clinical case can be made for apolipoprotein analysis to be widely available.
